Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Express Scripts
Covington
Boehringer Ingelheim
Daiichi Sankyo
McKinsey
US Department of Justice
Fuji
McKesson

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021254

« Back to Dashboard

NDA 021254 describes ADVAIR HFA, which is a drug marketed by Glaxo Grp Ltd and is included in one NDA. It is available from one supplier. There are fifteen patents protecting this drug. Additional details are available on the ADVAIR HFA profile page.

The generic ingredient in ADVAIR HFA is fluticasone propionate; salmeterol xinafoate. There are twenty-six drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the fluticasone propionate; salmeterol xinafoate profile page.
Summary for 021254
Tradename:ADVAIR HFA
Applicant:Glaxo Grp Ltd
Ingredient:fluticasone propionate; salmeterol xinafoate
Patents:15
Formulation / Manufacturing:see details
Pharmacology for NDA: 021254
Suppliers and Packaging for NDA: 021254
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ADVAIR HFA fluticasone propionate; salmeterol xinafoate AEROSOL, METERED;INHALATION 021254 NDA GlaxoSmithKline LLC 0173-0715 N 0173-0715-20
ADVAIR HFA fluticasone propionate; salmeterol xinafoate AEROSOL, METERED;INHALATION 021254 NDA GlaxoSmithKline LLC 0173-0715 N 0173-0715-22

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:AEROSOL, METERED;INHALATIONStrength0.045MG/INH;EQ 0.021MG BASE/INH
Approval Date:Jun 8, 2006TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jul 16, 2018Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Try a Free TrialPatent Expiration:Jun 23, 2018Product Flag?Substance Flag?Delist Request?
Patent:➤ Try a Free TrialPatent Expiration:Jun 23, 2018Product Flag?Substance Flag?Delist Request?

Expired US Patents for NDA 021254

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxo Grp Ltd ADVAIR HFA fluticasone propionate; salmeterol xinafoate AEROSOL, METERED;INHALATION 021254-002 Jun 8, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxo Grp Ltd ADVAIR HFA fluticasone propionate; salmeterol xinafoate AEROSOL, METERED;INHALATION 021254-002 Jun 8, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxo Grp Ltd ADVAIR HFA fluticasone propionate; salmeterol xinafoate AEROSOL, METERED;INHALATION 021254-003 Jun 8, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxo Grp Ltd ADVAIR HFA fluticasone propionate; salmeterol xinafoate AEROSOL, METERED;INHALATION 021254-003 Jun 8, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Chinese Patent Office
Johnson and Johnson
Daiichi Sankyo
Fuji
Dow
Moodys
Cantor Fitzgerald
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.